Randomized Phase III Trial of High–Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic MVAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924
Cora N. Sternberg(Cornell University), Laurence Collette(GlaxoSmithKline (Belgium)), Sophie D. Fosså(Oslo University Hospital), Michele Spina(National Cancer Institute), Christine Théodore(Hôpital Foch), C.J. van Groeningen(Fondazione Vincenzo Pansadoro), Jan H. Schornagel, A.T. van Oosterom(Fondazione Vincenzo Pansadoro), Christine de Balincourt(Fondazione Vincenzo Pansadoro), P.H.M. de Mulder(Fondazione Vincenzo Pansadoro), Fred Witjes(Fondazione Vincenzo Pansadoro)
Cited by 628
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Chemotherapy with Preoperative Radiotherapy in Rectal Cancer
|New England Journal of Medicine|2006|2.7k